Načítá se...
Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
BACKGROUND: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe. AIM: To compare the economic impact of two icatibant administration strategies: health profession...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3584739/ https://ncbi.nlm.nih.gov/pubmed/23398817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-1991-3-2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|